← Back

Wire · opportunities

FDA Approves Implantica RefluxStop for GERD Treatment

Published

25 August 2026

Topic

opportunities

Sectors

Medtech

Geography

United States

Source

Read at mddionline.com

Verified

Fusion42 · 25 August 2026 · Fusion42 review

The FDA granted premarket approval for Implantica's RefluxStop device for GERD treatment, opening the U.S. market following Johnson & Johnson's exit from non-U.S. markets for their competing device.

This Wire brief sits within Fusion42's coverage of Medtech, and 5 sources have reported it between 20 Aug 2026 and 25 Aug 2026.

◆ The Wire takeaway

You can now access the large U.S. GERD treatment market as Johnson & Johnson retreats from international competition. Prepare to engage key U.S. surgeons quickly to capitalise on this regulatory opening and establish an early foothold.

Coverage

5 sources · first reported 20 Aug 2026 · latest 25 Aug 2026

Related on Wire

Topics

Medtechgerdimplant-devicefda-approvalmedtechus-market